Tezepelumab reduces asthma exacerbations in diverse patient population

	Asthma
	The latest asthma news from News Medical

	Tezepelumab reduces asthma exacerbations in diverse patient population The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials.

	GLP-1 weight loss medications linked to significant drop in asthma flares New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

	Severe asthma patients often face multiple overlooked health conditions Most people living with severe asthma are also battling other health conditions that go under the radar, a major new study has found.

			New York City's mold-removal program reduces the burden of asthma exacerbations The New York City Housing Authority developed Mold Busters, a mold-removal program, in response to a 2013 class-action lawsuit filed by residents suffering from asthma due to mold in their apartments.

			Common allergy medication may also help fight aggressive cancers A drug widely used to treat asthma and allergies may also help fight aggressive cancers, reports a new Northwestern Medicine study that uncovered how tumors hijack common white blood cells to evade immunotherapy.

	Azithromycin fails to improve severe wheezing in preschool children A study led by researchers at the University of Arizona College of Medicine – Tucson showed that giving the antibiotic azithromycin did not help preschool children seen in the hospital emergency room with bouts of severe wheezing.

	Patient intuition leads to urgent open-heart surgery at NYU Langone Hospital—Brooklyn Shana Hale, a Brooklyn mother of two and a technology executive, noticed a mild burning sensation in her chest during her daily walks last summer.

	Bedfont® Scientific targets international growth at EAACI Congress 2026 Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at this year’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 at stand I03 to showcase its NObreath® and Gastrolyzer® range of non-invasive breath analysis devices.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2026